CLLS
Cellectis SANASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$352.14M
P/E Ratio
—
EPS
$-0.67
Beta
2.72
52W High
$5.48
52W Low
$1.33
50-Day MA
$3.71
200-Day MA
$3.77
Dividend Yield
—
Profit Margin
-89.50%
Forward P/E
—
PEG Ratio
0.00
About Cellectis SA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $75.11M |
| Gross Profit (TTM) | $75.11M |
| EBITDA | $-33.13M |
| Operating Margin | -333.40% |
| Return on Equity | -76.30% |
| Return on Assets | -8.43% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $0.60 |
| Price-to-Book | 5.88 |
| Price-to-Sales (TTM) | 4.69 |
| EV/Revenue | 3.805 |
| EV/EBITDA | -3.90 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -37.20% |
| Shares Outstanding | $72.61M |
| Float | $64.64M |
| % Insiders | 0.00% |
| % Institutions | 16.54% |
Historical Volatility
HV 10-Day
46.02%
HV 20-Day
55.68%
HV 30-Day
75.49%
HV 60-Day
69.70%
HV Rank
42.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($7.25 target)
1
Strong Buy2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026